Established in 1995, MacroMed is a specialty biopharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing its proprietary polymer technologies. MacroMed collaborates with major pharmaceutical and biotechnology companies and has its own pipeline of several products in various stages of preclinical and clinical development for cancer management (OncoGel®, Cytoryn), moderate to moderately severe pain (Dolotyn) and growth hormone deficiency (Ascentra).
NeuTec Pharma plc is a biopharmaceutical company formed in 1997 which specialises in the development of genetically recombinant antibodies, or "grabs", for the treatment of life-threatening infections. In February 2002 the Company's equity was admitted on the Alternative Investment Market ("AIM") of the London Stock Exchange. The development of NeuTec's products differs from the traditional approach used by conventional pharmaceutical companies that screen numerous chemical compounds for activity against bacteria and fungi. Many of these compounds will be too toxic for human use. In contrast, NeuTec identifies naturally occurring potentially protective antibodies from patients who have recovered from bacterial and fungal infections and then uses these to generate "grabs" to treat these infections. As a result, these "grabs" are likely to be intrinsically safer than antibiotics. NeuTec's two leading drug candidates are Mycograb®, which targets systemic candidiasis, and Aurograb®, which targets Staphylococcus aureus including methicillin-resistant Staphylococcus aureus ("MRSA"). NeuTec uses its platform technology Fabtec® for the identification of new therapeutic antibody fragments. This technology is available for licensing.
Vernalis is a UK-based specialty pharmaceutical company with two marketed products, Apokyn® to treat immobilising "off" episodes in patients with advanced Parkinson's disease and Frova®, to treat migraine. The company has a broad development pipeline focused on neurology and central nervous system disorders.
http://www.prestwickpharma.com
We are currently in the process of building a commercial organization to market and sell tetrabenazine in the U.S. upon regulatory approval. Cambridge Laboratories (Ireland), Limited, our licensor for tetrabenazine, has granted us exclusive rights to market and sell tetrabenazine in the U.S. and Canada. We have already established commercial operations in Canada to market and sell tetrabenazine. We are based in Washington, DC, and are privately held. In addition to a seasoned management team, we have a board of directors that includes senior executives from prominent venture capital firms, biopharmaceutical companies, and civic organizations. We are committed to becoming a leading specialty pharmaceutical company serving the CNS market.
Cephalon, Inc. is an international biopharmaceutical company engaged in the discovery, development and marketing of products to treat human diseases. The Company’s focuses its efforts in four core therapeutic areas: central nervous system (CNS) disorders, pain, cancer and addiction. In addition to conducting an active research and development program, it markets seven products in the United States and number of products in countries throughout Europe. The Company’s principal product is PROVIGIL (modafinil) Tablets (C-IV), which comprised approximately 49% of its total consolidated net sales during the year ended December 31, 2007, of which approximately 94% was in the United States market. In June 2007, the Company announced that it has received approval from FDA to market NUVIGIL (armodafinil) Tablets (C- IV).
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory